Bris­tol My­ers pulls lym­phoma in­di­ca­tion for Is­to­dax af­ter con­fir­ma­to­ry tri­al falls flat

Amid an in­dus­try­wide re­view of can­cer drugs with ac­cel­er­at­ed ap­proval, Bris­tol My­ers Squibb had to make the tough call last month to yank an ap­proval for lead­ing I/O drug Op­di­vo af­ter flop­ping a con­fir­ma­to­ry study. Now, a sec­ond Bris­tol My­ers drug is on the chop­ping block.

Bris­tol My­ers has pulled ag­ing HDAC in­hibitor Is­to­dax’s in­di­ca­tion in pe­riph­er­al T cell lym­phoma af­ter a Phase III con­fir­ma­to­ry study for the drug flopped on its pro­gres­sion-free sur­vival end­point, the drug­mak­er said Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER